Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-25T23:08:30.098Z Has data issue: false hasContentIssue false
  • English
  • Français

Healthcare costs and productivity losses in treatment-resistant depression in Finland

Published online by Cambridge University Press:  01 September 2022

S. Rannanpää ,
H. Taipale ,
A. Tanskanen ,
M. Lähteenvuo ,
S. Huoponen  and
J. Tiihonen
S. Rannanpää
Affiliation:
Janssen-Cilag, Medical Affairs, Neuroscience, Espoo, Finland
H. Taipale
Affiliation:
University of Eastern Finland, Department Of Forensic Psychiatry, Kuopio, Finland
A. Tanskanen
Affiliation:
University of Eastern Finland, Department Of Forensic Psychiatry, Kuopio, Finland
M. Lähteenvuo*
Affiliation:
University of Eastern Finland, Department Of Forensic Psychiatry, Kuopio, Finland
S. Huoponen
Affiliation:
Janssen-Cilag, Medical Affairs, Neuroscience, Espoo, Finland
J. Tiihonen
Affiliation:
University of Eastern Finland, Department Of Forensic Psychiatry, Kuopio, Finland
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Due to its relatively high prevalence and recurrent nature, depression causes a major burden on healthcare systems and societies.

Objectives

To investigate healthcare resource utilization and costs associated with treatment-resistant depression (TRD) compared with non-TRD depression in Finland.

Methods

Of all patients aged 16-65 years and diagnosed with depression in Finland during 2004-2016, persons with TRD (N=15 405) were identified from nationwide registers and matched 1:1 with comparison persons with depression but no TRD. TRD was defined as initiation of a third treatment trial after having failed two pharmacological treatment trials. Follow-up period covered five years after TRD or corresponding matching data (until end of 2018). Healthcare resource utilization was studied with negative binomial regression and average excess costs of TRD with generalized estimating equations, by adjusting for baseline costs, comorbidity and baseline severity of depression.

Results

Persons with TRD (mean age 38.7, SD 13.1, 60.0% women) had more healthcare utilization and work disability (sick leaves and disability pensions), adjusted incidence rate ratio for work disability days was 1.72 (95% CI 1.64-1.80). This resulted in higher total costs for persons with TRD, adjusted mean difference 7572 (95% CI 7215-7929) EUR per patient per year, higher productivity losses (due to sick leaves and disability pensions, mean difference 5296, 95% CI 5042-5550) and direct healthcare costs (2002, 95% CI 1853-2151) compared with non-TRD patients. Mean difference was highest during the first year after TRD (total costs difference 11760, 95% CI 11314-12206).

Conclusions

Treatment-resistant depression is associated with a significant cost burden.

Disclosure

This study was funded by Janssen-Cilag Finland and the Finnish Ministry of Social Affairs and Health through the developmental fund for Niuvanniemi Hospital. ML was partly funded by personal grants from the Finnish Medical Foundation and Emil Aaltonen fou

Keywords

treatment resistant depressionhealthcare utilizationcostDepression
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S268
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.